Jamieson is delighted to announce that it has advised the management teams of Huntsworth and Ashfield in connection with the take-private of UDG Healthcare plc (the parent of Ashfield) by CD&R.
Following the acquisition, Ashfield has been combined with Huntsworth (which was acquired by CD&R in 2020) to create Inizio, a strategic partner to health and life science companies throughout the life cycle of their drug products. Inizio offers a differentiated set of solutions to support pharma and biotech clients across the life cycle of a drug, from development to launch and beyond patent expiry. Sharp, the other key business segment of UDG, has been separated and will run as a standalone business.
“This was a very complex exercise, both legally and financially, involving merging an existing scheme with a new enlarged scheme and managing all the inter-connected parties. Stephen and the team did an outstanding job on behalf of all stakeholders”
The Jamieson team was led by Stephen Maxwell alongside Stuart Coventry, John Greenland, Matthew Mowat and Alison Dunning. The Jamieson team advised both the Huntsworth management team and the Ashfield management team on the new incentive arrangements following the combination. Jamieson also advised the management team of Sharp on their incentive arrangements following the separation.
